scholarly journals Ulcerative Colitis Endoscopic Index of Severity (UCEIS) versus Mayo Endoscopic Score (MES) in guiding the need for colectomy in patients with acute severe colitis

2017 ◽  
Vol 6 (1) ◽  
pp. 38-44 ◽  
Author(s):  
Tingbin Xie ◽  
Tenghui Zhang ◽  
Chao Ding ◽  
Xujie Dai ◽  
Yi Li ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Endoscopic Score ◽  
Index Of Severity ◽  
Acute Severe Colitis ◽  
Severe Colitis

P057 Gut microbiome diversity in acute severe colitis is distinct from mild-to-moderate ulcerative colitis

2019 ◽  
Vol 13 (Supplement_1) ◽  
pp. S114-S115
Author(s):  
S Kedia ◽  
T S Ghosh ◽  
B Das ◽  
S Jain ◽  
S Bopanna ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Gut Microbiome ◽  
Microbiome Diversity ◽  
Acute Severe Colitis ◽  
Severe Colitis

scholarly journals P177 Prognostic factors for colectomy and acute severe colitis in paediatric ulcerative colitis: A systematic review

2018 ◽  
Vol 12 (supplement_1) ◽  
pp. S188-S188
Author(s):  
E Orlanski-Meyer ◽  
M Aardoom ◽  
A Ricciuto ◽  
N Carman ◽  
L de Ridder ◽  
...  
Keyword(s):  
Systematic Review ◽  
Ulcerative Colitis ◽  
Prognostic Factors ◽  
Acute Severe Colitis ◽  
Severe Colitis

scholarly journals Endoscopic and Histologic Predictors of Outcomes in Pediatric Ulcerative Colitis—Caveat Emptor

2021 ◽  
Vol 9 ◽  
Author(s):  
Lorraine Stallard ◽  
Séamus Hussey
Keyword(s):  
Ulcerative Colitis ◽  
Mucosal Healing ◽  
Term Treatment ◽  
Clinical Settings ◽  
Adult Disease ◽  
Long Term Treatment ◽  
Acute Severe Colitis ◽  
The Impact ◽  
Severe Colitis

The impact of endoscopic and histological mucosal healing on outcomes in adult settings is impressive. Despite many clinical parallels, pediatric ulcerative colitis (UC) is set apart from adult disease in several respects. Many frequently used indices are not fully validated, especially in pediatric settings, and consensus on precise definitions in clinical settings are lacking. Endoscopic mucosal healing is an acceptable long-term treatment goal in pediatrics, but not histologic normalization. Early prediction of disease course in UC may allow treatment stratification of patients according to risks of relapse, acute severe colitis, and colectomy. Putative endoscopic and histologic predictors of poor clinical outcomes in adults have not held true in pediatric settings, including baseline endoscopic extent, endoscopic severity, and specific histologic characteristics which are less prevalent in pediatrics at diagnosis. In this mini-review we appraise predictive endoscopic and histologic factors in pediatric UC with reference to relapse, severe colitis, and colectomy risks. We recommend that clinicians routinely use endoscopic and histologic sores to improve the quality of clinical and research practice. The review summarizes differences between adult and pediatric prediction data, advises special consideration of those with primary sclerosing cholangitis, and suggests areas for future study in this field.

Ulcerative colitis

2018 ◽  
Author(s):  
Akshay Batra ◽  
Mark Beattie
Keyword(s):  
Ulcerative Colitis ◽  
Risks And Benefits ◽  
Acute Severe Colitis ◽  
Severe Colitis

This chapter discusses the presentation and management of ulcerative colitis with a special emphasis on management of acute severe colitis. Risks and benefits associated with different therapies are described.

scholarly journals Management of Acute Severe Colitis in the Era of Biologicals and Small Molecules

2019 ◽  
Vol 8 (12) ◽  
pp. 2169
Author(s):  
Christine Verdon ◽  
Talat Bessissow ◽  
Peter L. Lakatos
Keyword(s):  
Ulcerative Colitis ◽  
Small Molecules ◽  
Patient Monitoring ◽  
Treatment Options ◽  
Medical Emergency ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
New Treatment ◽  
Acute Severe Colitis ◽  
Severe Colitis

Acute severe ulcerative colitis (ASUC) is a medical emergency which occurs in about 20%–30% of patients with ulcerative colitis during their lifetime, and does carry a mortality risk of 1%. The management of inflammatory bowel diseases has evolved with changes in objective patient monitoring, as well as the availability of new treatment options with the development of new biological and small molecules; however, data is limited regarding their use in the context of ASUC. This review aims to discuss the emerging data regarding biologicals and small molecules therapies in the context of ASUC.

scholarly journals Tu1792 – Gut Microbiome Diversity in Acute Severe Colitis is Distinct from Mild to Moderate Ulcerative Colitis

2019 ◽  
Vol 156 (6) ◽  
pp. S-1125-S-1126
Author(s):  
Saurabh Kedia ◽  
Bhabatosh Das ◽  
Tarini Shankar Ghosh ◽  
Saransh Jain ◽  
Vipin Gupta ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Gut Microbiome ◽  
Microbiome Diversity ◽  
Acute Severe Colitis ◽  
Severe Colitis

scholarly journals P561 Ulcerative Colitis Endoscopic Index of Severity (UCEIS) and Mayo Endoscopic Score (MES) in predicting the therapeutic effect of mesalazine in UC patients

2021 ◽  
Vol 15 (Supplement_1) ◽  
pp. S524-S525
Author(s):  
L Wu ◽  
Y Zhang ◽  
Q Cao
Keyword(s):  
Ulcerative Colitis ◽  
High Probability ◽  
Primary Outcome ◽  
Demographic Data ◽  
Clinical Observations ◽  
Previous Therapy ◽  
Endoscopic Score ◽  
Index Of Severity ◽  
Roc Area

Abstract Background The Ulcerative Colitis Endoscopic Index of Severity (UCEIS) and the Mayo Endoscopic Score (MES) were developed as an objective method of the endoscopic severity in ulcerative colitis (UC); however, it was still unclear whether UCEIS and MES could guide the mesalazine treatment in UC. Methods Consecutive UC patients who had undergone colonoscopy within 1 month before starting mesalazine between October 2011 and July 2016 were retrospectively evaluated. Demographic data, previous therapy, clinical observations, laboratory parameters, medical therapy and endoscopic assessments were documented. The primary outcome was the need for ‘step up’ treatment (containing the use of corticosteroids, immunomodulatory or surgery.) during admission and follow-up. Results Sixty-five patients were enrolled, 12(18.5%) needed ‘step up’ treatment’ due to primary or secondary nonresponse to mesalazine. UCEIS score is a predictor of primary or secondary nonresponse to mesalazine in multivariate analysis (OR, 25.65; 95% CI, 3.048–45.985; P =0.003). Receiver-operator characteristic (ROC) area of UCEIS is 0.95, with a sensitivity of 100% and specificity of 84.6%, using cut-off value of 6, which outperforms MES with the ROC area of 0.70; When UCEIS score ≥6, 60% of patients eventually need ‘step up’ treatment. Conclusion UCEIS score is a useful instrument for evaluating endoscopic improvement in UC patients treated with mesalazine. The high probability of mesalazine treatment failure and benefits of other therapy should be discussed in patients with baseline UCEIS ≥ 6.

Sign in / Sign up

Export Citation Format

Share Document